Penserra Capital Management LLC bought a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 19,112 shares of the company's stock, valued at approximately $2,229,000.
A number of other hedge funds have also bought and sold shares of the company. NBC Securities Inc. bought a new stake in Axsome Therapeutics during the 1st quarter valued at about $31,000. Raiffeisen Bank International AG bought a new position in shares of Axsome Therapeutics during the 4th quarter worth approximately $51,000. Assetmark Inc. purchased a new stake in shares of Axsome Therapeutics during the 4th quarter valued at $52,000. Aquatic Capital Management LLC purchased a new stake in shares of Axsome Therapeutics during the fourth quarter worth about $76,000. Finally, GF Fund Management CO. LTD. purchased a new stake in Axsome Therapeutics during the 4th quarter worth approximately $86,000. Institutional investors own 81.49% of the company's stock.
Insiders Place Their Bets
In other Axsome Therapeutics news, General Counsel Hunter R. Murdock sold 7,500 shares of the company's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $100.26, for a total value of $751,950.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Mark Coleman sold 3,750 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total transaction of $395,512.50. Following the transaction, the director owned 50,387 shares of the company's stock, valued at $5,314,316.89. This trade represents a 6.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 93,437 shares of company stock worth $9,834,215. 22.30% of the stock is owned by corporate insiders.
Axsome Therapeutics Stock Performance
NASDAQ AXSM traded up $3.94 during trading hours on Wednesday, hitting $112.35. 886,863 shares of the stock were exchanged, compared to its average volume of 668,852. The company has a quick ratio of 1.96, a current ratio of 2.03 and a debt-to-equity ratio of 3.48. The stock has a 50-day moving average of $106.61 and a 200 day moving average of $107.95. The company has a market cap of $5.53 billion, a price-to-earnings ratio of -19.47 and a beta of 0.46. Axsome Therapeutics, Inc. has a 12-month low of $72.21 and a 12-month high of $139.13.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the company. Royal Bank Of Canada reduced their price objective on Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating for the company in a research note on Thursday, June 12th. Wells Fargo & Company restated an "overweight" rating and issued a $165.00 price target (up previously from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 6th. Needham & Company LLC decreased their price objective on shares of Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating on the stock in a report on Monday, June 9th. Morgan Stanley assumed coverage on Axsome Therapeutics in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $190.00 target price on the stock. Finally, Cantor Fitzgerald raised shares of Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Axsome Therapeutics presently has an average rating of "Buy" and an average price target of $172.33.
Get Our Latest Analysis on Axsome Therapeutics
Axsome Therapeutics Profile
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Read More

Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.